Absolute bioavailability and metabolic disposition of valaciclovir, the L-valyl ester of acyclovir, following oral administration to humans.

Antimicrobial Agents and Chemotherapy
J Soul-LawtonJ Posner

Abstract

Valaciclovir (Valtrex), the L-valyl ester of acyclovir, is undergoing clinical development for the treatment and suppression of herpesviral diseases. The absolute bioavailability of acyclovir from valaciclovir and the metabolic disposition of valaciclovir were investigated with healthy volunteers in two separate studies. In a randomized, crossover study, 12 fasting healthy volunteers each received 1,000 mg of oral valaciclovir and a 1-h intravenous infusion of 350 mg of acyclovir. The mean absolute bioavailability of acyclovir was 54.2%, a value three to five times that obtained previously with oral acyclovir. A similar estimate of 51.3% was made from urinary recovery of acyclovir. In the second study, four fasting volunteers received a single oral dose of 1,000 mg of [14C]valaciclovir. The majority of plasma radioactivity was accounted for by acyclovir, with very low plasma valaciclovir concentrations (mean maximum concentration of drug in plasma = 0.19 microM), which were undetectable after 3 h postdose. By 168 h, more than 90% of the administered radioactive dose was recovered, with approximately 45% in urine and 475 in feces. More than 99% of the radioactivity recovered in urine corresponded to acyclovir and its known metab...Continue Reading

References

Jan 14, 1988·The New England Journal of Medicine·J D MeyersE D Thomas
Sep 1, 1983·The Journal of Antimicrobial Chemotherapy·P de Miranda, M R Blum
Nov 1, 1981·Clinical Pharmacology and Therapeutics·P de MirandaP S Lietman
Dec 18, 2002·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Edward L MattiuzJohn-Michael Sauer

❮ Previous
Next ❯

Citations

Oct 20, 2009·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·P RautenbergH Fickenscher
Jul 20, 2006·Pharmaceutical Research·Nada AblaYogeshvar N Kalia
Jul 2, 1999·Obstetrics and Gynecology·D A BakerJ M Miller
Jul 11, 2003·Clinical Therapeutics·Devada Singh, Deborah H Kennedy
Aug 26, 1998·Antiviral Research·J W Cohen StuartR J Whitley
Jan 29, 2000·Antiviral Research·R J Whitley, J W Gnann
Jan 16, 2003·Journal of Controlled Release : Official Journal of the Controlled Release Society·Anne Engelbrecht ThomsenBente Steffansen
Jul 18, 2002·Dermatologic Clinics·Kimberly A Yeung-YueStephen K Tyring
Jul 13, 2002·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Gerda Marie FriedrichsenRonald T Borchardt
Jun 6, 2006·Molecular Pharmaceutics·Anand Balakrishnan, James E Polli
Jan 24, 2013·Molecular Pharmaceutics·Ivan S KrylovCharles E McKenna
Apr 23, 2002·Dermatologic Surgery : Official Publication for American Society for Dermatologic Surgery [et Al.]·William H Beeson, John D Rachel
Apr 22, 1999·The New England Journal of Medicine·H H Balfour
Feb 8, 2008·The Journal of Biological Chemistry·Longsheng LaiGordon L Amidon
May 16, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Anders HelldénLars Ståhle
Sep 16, 2005·Clinical Journal of Sport Medicine : Official Journal of the Canadian Academy of Sport Medicine·B J Anderson
Sep 4, 2009·Current Opinion in Infectious Diseases·Christophe VanpouilleLeonid Margolis
Dec 25, 2012·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Bei Yang, David E Smith
May 18, 2011·Antimicrobial Agents and Chemotherapy·Thomas PouplinTran Thi Hong Chau
Sep 6, 2012·BMC Ophthalmology·Simon Rj TaylorSue L Lightman
Feb 24, 2007·Journal of Zoo and Wildlife Medicine : Official Publication of the American Association of Zoo Veterinarians·Maria J L KikGerry M Dorrestein
Feb 20, 2010·Clinical Ophthalmology·Patrick M K TamSusan Lightman
Jan 11, 2001·Drugs·D T Leung, S L Sacks
Aug 12, 2003·PharmacoEconomics·Mathijs H BrentjensStephen K Tyring
Feb 24, 2006·American Journal of Clinical Dermatology·Hiok-Hee Tan, Chee-Leok Goh
Nov 26, 2013·Medicina clínica·María Carmen Alarcón GarcelánPatricia Rodríguez Torres
Oct 27, 2012·Advanced Drug Delivery Reviews·Balvinder S VigJarkko Rautio
Sep 21, 2013·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·C SpiraB Seitz
Mar 21, 2007·Digestive Diseases and Sciences·Genia RadevaRobert Farinotti

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antivirals

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antivirals (ASM)

Antivirals are medications that are used specifically for treating viral infections. Discover the latest research on antivirals here.